Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • Schlich China
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy
  • Patent Specialities
    • Life Sciences & Biotech
    • Chemical & Pharmaceutical
    • Mechanical, Engineering and Physics
    • Software, Electronics and Communications
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
Is an Intervener an Opponent or Appellant, or just an Intervener?

Is an Intervener an Opponent or Appellant, or just an Intervener?

by Juliette Boynton | Jan 27, 2025 | EPO

This issue was previously considered by the Enlarged Board in G3/04, who concluded that the Appeal could not be continued. The G3/04 decision notes that the status of an intervener is defined in Article 105 EPC which states:- Any third party may, in accordance with...
What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…

What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…

by Sean Hutchinson | Aug 30, 2024 | EPO

Background European patent no. EP 2 991 507 B1 was granted with claims directed to a mixture containing fish oil and fruit juice for use in the treatment of cancer. At opposition, the patent was found to lack novelty and the amendments proposed by the patent...
Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims

Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims

by Chloe Sullivan | Aug 29, 2024 | EPO, Uncategorised

Background Due to methods of treatment of the human or animal body being excluded from patentability in Europe, applicants are required to claim substances or compositions for use in a method of treatment instead. Thus, there is a need for the term “substances or...
Updates to the Guidelines for Examination in the EPO – 2024

Updates to the Guidelines for Examination in the EPO – 2024

by Carolyn Haywood | Mar 26, 2024 | EPO

Priority Historically, the EPO have assessed formal entitlement to priority quite strictly. In scenarios where a priority application is filed by joint applicants, all of them, or their respective successors in title, must be named on the subsequent priority claiming...
Back in the Maze: Is the Decision of the Referring Board in G 2/21 About to be Overturned?

Back in the Maze: Is the Decision of the Referring Board in G 2/21 About to be Overturned?

by Sean Hutchinson | Jan 25, 2024 | EPO

When the EPO’s Enlarged Board of Appeal issued its decision in G 2/21 (the “plausibility” referral), many were left wondering what the requirements were for a patent applicant/proprietor to be able to rely on post-filed evidence in support of inventive step. However,...
« Older Entries
Next Entries »

Recent Posts

  • By Touatis! “Obelix®” Has A Reputation
  • Schlich recognised in IAM Patent 1000 rankings for 2026
  • First UPC Referral to the CJEU: Just How Long is the Long-Arm Jurisdiction of the UPC?
  • Sequence Identity Claims After T 0137/24: How Broad Is Too Broad?
  • Schlich’s 2026 Reception Aboard the Golden Hinde

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy

    About

    • Our Firm
    • Careers
    • Our People
    • Policies

    Contact

    • Contact
    • Inventors Zone
    © 2026 Schlich, All rights reserved | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.